Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
GTXI's Cash to Debt is ranked higher than
96% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. GTXI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GTXI' s Cash to Debt Range Over the Past 10 Years
Min: 1890.4  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
GTXI's Interest Coverage is ranked higher than
94% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GTXI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GTXI' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -19.73
M-Score: -4.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -865.28
GTXI's ROE (%) is ranked lower than
98% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. GTXI: -865.28 )
Ranked among companies with meaningful ROE (%) only.
GTXI' s ROE (%) Range Over the Past 10 Years
Min: -397.59  Med: -53.73 Max: 71.17
Current: -865.28
-397.59
71.17
ROA (%) -79.37
GTXI's ROA (%) is ranked lower than
82% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. GTXI: -79.37 )
Ranked among companies with meaningful ROA (%) only.
GTXI' s ROA (%) Range Over the Past 10 Years
Min: -118.97  Med: -43.15 Max: 25.08
Current: -79.37
-118.97
25.08
ROC (Joel Greenblatt) (%) -99719.63
GTXI's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. GTXI: -99719.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GTXI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -43046.81  Med: -2319.25 Max: 522.64
Current: -99719.63
-43046.81
522.64
Revenue Growth (3Y)(%) -100.00
GTXI's Revenue Growth (3Y)(%) is ranked lower than
93% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. GTXI: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GTXI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100.00 Max: 98.3
Current: -100
0
98.3
EBITDA Growth (3Y)(%) -15.40
GTXI's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. GTXI: -15.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GTXI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -15.40 Max: 10.5
Current: -15.4
0
10.5
EPS Growth (3Y)(%) -7.20
GTXI's EPS Growth (3Y)(%) is ranked lower than
54% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. GTXI: -7.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GTXI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.8  Med: -4.80 Max: 194
Current: -7.2
-54.8
194
» GTXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

GTXI Guru Trades in Q4 2014

Paul Tudor Jones 34,033 sh (-7.29%)
» More
Q1 2015

GTXI Guru Trades in Q1 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
Q2 2015

GTXI Guru Trades in Q2 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
Q3 2015

GTXI Guru Trades in Q3 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GTXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 22.33
GTXI's P/B is ranked lower than
99.99% of the 1123 Companies
in the Global Biotechnology industry.

( Industry Median: 2.60 vs. GTXI: 22.33 )
Ranked among companies with meaningful P/B only.
GTXI' s P/B Range Over the Past 10 Years
Min: 0.44  Med: 4.49 Max: 32.88
Current: 22.33
0.44
32.88
Current Ratio 1.10
GTXI's Current Ratio is ranked lower than
87% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. GTXI: 1.10 )
Ranked among companies with meaningful Current Ratio only.
GTXI' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.33 Max: 21.23
Current: 1.1
0.56
21.23
Quick Ratio 1.10
GTXI's Quick Ratio is ranked lower than
83% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GTXI: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
GTXI' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.33 Max: 21.22
Current: 1.1
0.56
21.22

Valuation & Return

vs
industry
vs
history
Price/Net Cash 66.00
GTXI's Price/Net Cash is ranked higher than
51% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 18.00 vs. GTXI: 66.00 )
Ranked among companies with meaningful Price/Net Cash only.
GTXI' s Price/Net Cash Range Over the Past 10 Years
Min: 2.7  Med: 7.22 Max: 307.67
Current: 66
2.7
307.67
Price/Net Current Asset Value 33.00
GTXI's Price/Net Current Asset Value is ranked lower than
53% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. GTXI: 33.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GTXI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.64  Med: 6.13 Max: 76.92
Current: 33
2.64
76.92
Price/Tangible Book 33.00
GTXI's Price/Tangible Book is ranked lower than
62% of the 1051 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. GTXI: 33.00 )
Ranked among companies with meaningful Price/Tangible Book only.
GTXI' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.6  Med: 6.13 Max: 43.95
Current: 33
2.6
43.95
Price/Graham Number 0.39
GTXI's Price/Graham Number is ranked higher than
90% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. GTXI: 0.39 )
Ranked among companies with meaningful Price/Graham Number only.
GTXI' s Price/Graham Number Range Over the Past 10 Years
Min: 0.84  Med: 1.44 Max: 7.36
Current: 0.39
0.84
7.36
Earnings Yield (Greenblatt) (%) -35.76
GTXI's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. GTXI: -35.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GTXI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -36.6  Med: 159.80 Max: 3978.9
Current: -35.76
-36.6
3978.9

More Statistics

Revenue(Mil) $14
EPS $ -0.53
Beta2.27
Short Percentage of Float4.97%
52-Week Range $0.29 - 1.59
Shares Outstanding(Mil)140.37

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil)
EPS($) -0.19 -0.14 -0.15
EPS without NRI($) -0.19 -0.14 -0.15

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GTU.Germany,
GTx Inc is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). They are conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. The Company is developing GTx-758, an oral luteinizing hormone, or LH, inhibitor for the treatment of advanced prostate cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The Company's most advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions.
» More Articles for GTXI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: GTx, Inc, VIVUS, Inc, Time Warner Inc. Jul 22 2012 
Weekly CEO Sells Highlight: GTX, Signet Group, Qlik Tech, Voxx Apr 16 2012 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2010 
GTx Inc. Reports Operating Results (10-Q) Aug 09 2010 
GTx Inc. Reports Operating Results (10-Q) May 04 2010 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2009 
GTx Inc. Reports Operating Results (10-Q) Aug 10 2009 
GTx Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 13 2016
GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence Jan 13 2016
GTX INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Dec 23 2015
BIOSTAR GeForce GAMING GTX 750 Ti OC: The Gamer Graphics Card - More performance for the gamer... Dec 18 2015
Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session Dec 16 2015
GTX INC /DE/ Financials Dec 08 2015
Equities on the Move - Research on GTX Inc, Juniper Pharmaceuticals, Catabasis Pharmaceuticals and... Dec 01 2015
Is Jernigan Capital Inc (JCAP) a Good Stock To Buy? Nov 29 2015
Radio One, Inc. (ROIAK): Are Hedge Funds Right About This Stock? Nov 26 2015
GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Nov 23 2015
BIOSTAR GEFORCE GAMING GTX 950 ANNOUNCED, COMPETITIVE GAMING AT A COMPETITIVE PRICE - Impact Your... Nov 23 2015
GTX INC /DE/ Files SEC form 10-Q, Quarterly Report Nov 09 2015
Affordable and Powerful Gaming with BIOSTAR's GeForce GTX 750 Ti VGA Card and Hi-Fi Z170Z5 Mainboard... Nov 04 2015
Edited Transcript of GTXI earnings conference call or presentation 29-Oct-15 1:00pm GMT Nov 02 2015
GTx posts 3Q profit Oct 29 2015
GTx posts 3Q profit Oct 29 2015
GTX Inc Earnings Call scheduled for 9:00 am ET today Oct 29 2015
GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 29 2015
GTx Provides Corporate Update and Reports Third Quarter 2015 Financial Results Oct 29 2015
GTx Provides Corporate Update and Reports Third Quarter 2015 Financial Results Oct 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK